Braveheart Bio director buys 83,333 shares
Braveheart Bio, Inc. director Christopher Viehbacher reported buying 83,333 shares of common stock at $18.00 per share on August 7, 2026, bringing his direct holdings to 609,519 shares.
Rhea-AI Filing Summary
Braveheart Bio, Inc. director Christopher Viehbacher reported buying 83,333 shares of common stock at $18.00 per share on August 7, 2026, bringing his direct holdings to 609,519 shares. He also received a stock option for 30,000 shares at an exercise price of $18.00, expiring August 4, 2036; these options vest in full on the earlier of August 5, 2027 or the next annual stockholders’ meeting, subject to continued service. In addition, 150,338 shares are held indirectly through CAV FAMILY LLC, with beneficial ownership disclaimed except for any pecuniary interest.
Positive
- None.
Negative
- None.
Insights
Analyzing...
Insider Trade Summary
Net Buyer: 83,333 shares
Net Buy
3 txns
Insider
Viehbacher Christopher
Role
Director
Bought
83,333 shs ($1.50M)
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Purchase | Common Stock | 83,333 | $18.00 | $1.50M |
| Grant/Award | Stock Option (Right to Buy) F2 | 30,000 | $0.00 | $0.00 |
| holding | Common Stock F1 | -- | -- | -- |
Holdings After Transaction:
Stock Option (Right to Buy) — 30,000 contracts (Direct);
Common Stock — 609,519 shares (Direct);
Common Stock — 150,338 shares (Indirect, By CAV FAMILY LLC)
Footnotes (2)
- F1. The Reporting Person disclaims beneficial ownership of such securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of his pecuniary interest therein, if any. This report shall not be deemed an admission that the Reporting Person is the beneficial owner of such securities for purposes of Section 16 of the Exchange Act or for any other purpose.
- F2. The shares underlying the stock option will vest in full upon the earlier of (i) August 5, 2027 or (ii) the date of the Issuer's next annual meeting of stockholders, subject to the Reporting Person's continued service to the Issuer through such vesting date.
Key Figures
Common shares purchased: 83,333 shares
Purchase price: $18.00 per share
Direct holdings after purchase: 609,519 shares
+4 more
7 metrics
Common shares purchased
83,333 shares
Open-market or private purchase on August 7, 2026 at $18.00 per share
Purchase price
$18.00 per share
Price paid for 83,333 common shares on August 7, 2026
Direct holdings after purchase
609,519 shares
Total common stock directly owned by Viehbacher following the August 7, 2026 trade
Option grant size
30,000 shares
Stock option (right to buy) granted August 5, 2026
Option exercise price
$18.00 per share
Exercise price for 30,000-share stock option expiring August 4, 2036
Option expiration date
August 4, 2036
Expiration of stock option for 30,000 underlying common shares
Indirectly held shares
150,338 shares
Common stock held indirectly by CAV FAMILY LLC with beneficial ownership disclaimed in part
Key Terms
stock option, pecuniary interest, indirect ownership, Rule 10b5-1
4 terms
stock option financial
"The shares underlying the stock option will vest in full upon the earlier"
A stock option is a contract that gives you the right to buy or sell a company's stock at a specific price within a certain time frame. People use them to potentially make money if the stock's price moves favorably or to protect against losses. It's like holding a coupon that can be used to buy or sell stock at a set price later on.
pecuniary interest financial
"except to the extent of his pecuniary interest therein, if any"
indirect ownership financial
"Common Stock holding entry shows indirect ownership by CAV FAMILY LLC"
Rule 10b5-1 regulatory
"aff_10b5_one field represents the Rule 10b5-1 plan checkbox status"
Rule 10b5-1 is a regulation that allows company insiders to buy or sell their shares at predetermined times, even if they have access to non-public information. It acts like setting a schedule in advance for transactions, helping prevent accusations of unfair trading. This rule provides a way for insiders to plan trades transparently, giving investors confidence that these transactions are not based on hidden information.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What insider transactions did BRVE director Christopher Viehbacher report?
Christopher Viehbacher reported buying 83,333 BRVE common shares at $18.00 on August 7, 2026 and receiving a stock option for 30,000 shares at an $18.00 exercise price, expiring August 4, 2036, subject to vesting conditions.
What are the key terms of Christopher Viehbacher’s new BRVE stock option grant?
The grant is a stock option for 30,000 BRVE shares with an $18.00 per-share exercise price, expiring on August 4, 2036. It vests in full on the earlier of August 5, 2027 or the next annual stockholders’ meeting, subject to continued service.
How is Viehbacher’s indirect ownership in BRVE through CAV FAMILY LLC described?
The filing shows 150,338 BRVE shares held indirectly "By CAV FAMILY LLC". Viehbacher disclaims beneficial ownership of these securities for Section 16 purposes, except to the extent of his pecuniary interest, if any.
AI-generated analysis. How Rhea-AI works. Not financial advice.
